DrugPatentWatch Database Preview
Drugs in Development Information for N91115
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for N91115?
N91115 is an investigational drug.
There have been 8 clinical trials for N91115.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2019.
The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Asthma. The leading clinical trial sponsors are Nivalis Therapeutics, Inc., University of North Carolina, Chapel Hill, and National Heart, Lung, and Blood Institute (NHLBI).
There are ten US patents protecting this investigational drug and forty-five international patents.
Summary for N91115
| US Patents | 10 |
| International Patents | 45 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2019-11-01) |
| Vendors | 4 |
Recent Clinical Trials for N91115
| Title | Sponsor | Phase |
|---|---|---|
| PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study | University of North Carolina, Chapel Hill | Phase 2 |
| MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9) | Nivalis Therapeutics, Inc. | Phase 1 |
Clinical Trial Summary for N91115
Top disease conditions for N91115
Top clinical trial sponsors for N91115
US Patents for N91115
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| N91115 | Start Trial | Solid forms of an S-Nitrosoglutathione reductase inhibitor | LAUREL THERAPEUTICS LTD. (Hangzhou, Zhejiang Province, CN) | Start Trial |
| N91115 | Start Trial | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | N30 Pharmaceuticals, Inc. (Boulder, CO) | Start Trial |
| N91115 | Start Trial | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | N30 Pharmaceuticals, Inc. (Boulder, CO) | Start Trial |
| N91115 | Start Trial | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | Nivalis Therapeutics, Inc. (Boulder, CO) | Start Trial |
| N91115 | Start Trial | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | Nivalis Therapeutics, Inc. (Boulder, CO) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for N91115
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| N91115 | World Intellectual Property Organization (WIPO) | 2017044766 | 2035-09-10 | Start Trial |
| N91115 | World Intellectual Property Organization (WIPO) | 2017044788 | 2035-09-10 | Start Trial |
| N91115 | Australia | 2011343518 | 2030-12-16 | Start Trial |
| N91115 | Brazil | 112013014681 | 2030-12-16 | Start Trial |
| N91115 | Canada | 2821412 | 2030-12-16 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
